PT - JOURNAL ARTICLE AU - Duckworth, Anna AU - Gibbons, Michael A. AU - Allen, Richard J. AU - Almond, Howard AU - Beaumont, Robin N. AU - Wood, Andrew R. AU - Lunnon, Katie AU - Lindsay, Mark A. AU - Wain, Louise V. AU - Tyrrell, Jess AU - Scotton, Chris J. TI - Evidence that Telomere Length is Causal for Idiopathic Pulmonary Fibrosis but not Chronic Obstructive Pulmonary Disease: A Mendelian Randomisation Study AID - 10.1101/2020.02.05.20019653 DP - 2020 Jan 01 TA - medRxiv PG - 2020.02.05.20019653 4099 - http://medrxiv.org/content/early/2020/02/07/2020.02.05.20019653.short 4100 - http://medrxiv.org/content/early/2020/02/07/2020.02.05.20019653.full AB - Background Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease accounting for 1% of UK deaths. In the familial form of pulmonary fibrosis, causal genes have been identified in ∼30% of cases, and a majority relate to telomere maintenance. Prematurely shortened leukocyte telomere length has also been associated with IPF, as well as chronic obstructive pulmonary disease (COPD), a disease with a similar demographic and shared risk factors. Using Mendelian randomisation (MR), our study aimed to determine whether short telomeres cause IPF or COPD.Methods We performed an MR study for telomere length causality in IPF and COPD with up to 1,369 IPF cases, 14,103 COPD cases and 435,866 controls of European ancestry in UK Biobank. Initial studies using polygenic risk scores followed by two-sample MR analyses were carried out using seven genetic variants previously associated with telomere length, with replication analysis in an IPF cohort of 2,668 IPF cases and 8,591 controls and a COPD cohort of 15,256 cases and 47,936 controls.Findings Meta-analysis of the two-sample MR results provided evidence that shorter telomeres cause IPF, with a genetically instrumented one standard deviation shorter telomere length associated with 5.81 higher odds of IPF ([95% CI: 3.56-9.50], P=2.19×10−12. Despite being an age-related lung disease with overlapping risk, there was no evidence that telomere length caused COPD (OR 1.07, [95% CI 0.90-1.27], P = 0.46).Interpretation Cellular senescence is hypothesised as a major driving force in both IPF and COPD; telomere shortening may be a contributory factor in IPF, suggesting divergent mechanisms in COPD. This enables greater focus in telomere-related diagnostics, treatments and the search for a cure in IPF. Therapies manifesting improvements in telomere length, including safe telomere activation therapy, may warrant investigation.Competing Interest StatementM. Gibbons has received support to attend conferences and professional fees from Roche and Boehringer-IngelheimFunding StatementA. Duckworth is funded by the GW4 MRC Doctoral Training Partnership. M. Gibbons has received support to attend conferences and professional fees from Roche and Boehringer-Ingelheim L. Wain holds a GSK/British Lung Foundation Chair in Respiratory Research. J. Tyrrell is supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, GCRF, the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK [SBF004\1079]. R. Allen is an Action for Pulmonary Fibrosis Research Fellow. The Research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of HealthAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank is an open access resource. The Resource is open to bona fide scientists, undertaking health-related research that is in the public good. Approved scientists from the UK and overseas and from academia, government, charity and commercial companies can apply to use the Resource. Replication cohort summary statistics for the IPF GWAS are available via application at the URL below. Replication cohort summary statistics for the COPD GWAS are available on request at the URL below. https://www.ukbiobank.ac.uk/ https://github.com/genomicsITER/PFgenetics https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381275/